For a new analyzer of an approved PSA test with no new clinical data, what PMA supplement is required?

For a new analyzer of an approved PSA test with no new clinical data, what PMA supplement is required?

• A. Special PMA Supplements Changes Being Affected
• B. 30 day Notice
• C. Real Time Supplement
• D. 180-Day Supplement

Answer: (D)

In the context of regulatory submissions for medical devices, specifically for a new analyzer of an already approved PSA test where no new clinical data is introduced, the correct approach is to submit a 180-Day Supplement. This type of supplement is typically utilized for changes in manufacturing or design that do not significantly affect the safety or effectiveness of the already approved product. The 180-Day Supplement allows manufacturers to make modifications that are somewhat significant, but not extensive enough to merit a new premarket approval (PMA) application. This is particularly relevant when the changes are primarily related to enhancing the device’s performance, to improve certain aspects of the manufacturing process, or to address issues with existing designs without altering the fundamental safety profile of the device. Choosing this route also reflects an understanding of the regulatory flexibility provided for device modifications that maintain already established safety and effectiveness benchmarks without requiring a full re-evaluation based on new clinical data.

In the context of regulatory submissions for medical devices, specifically for a new analyzer of an already approved PSA test where no new clinical data is introduced, the correct approach is to submit a 180-Day Supplement. This type of supplement is typically utilized for changes in manufacturing or design that do not significantly affect the safety or effectiveness of the already approved product.

The 180-Day Supplement allows manufacturers to make modifications that are somewhat significant, but not extensive enough to merit a new premarket approval (PMA) application. This is particularly relevant when the changes are primarily related to enhancing the device’s performance, to improve certain aspects of the manufacturing process, or to address issues with existing designs without altering the fundamental safety profile of the device.

Choosing this route also reflects an understanding of the regulatory flexibility provided for device modifications that maintain already established safety and effectiveness benchmarks without requiring a full re-evaluation based on new clinical data.